AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s investigational antibody-drug conjugates. Genmab acquired ProfoundBio in May 2024.
AbbVie Lawsuit Alleges That Partner Genmab “Misappropriated” Trade Secrets